Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis

Lignende værker

• Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study
  af: Tanaka, Yosuke, et al.
  Udgivet: (2017)
• A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy
  af: Naito, Tomoyuki, et al.
  Udgivet: (2017)
• Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia
  af: Corte, Tamera J., et al.
  Udgivet: (2014)
• Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
  af: Shimomura, Iwao, et al.
  Udgivet: (2018)
• Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis
  af: Sakao, Seiichiro, et al.
  Udgivet: (2019)